Dr. Hedy Lee KindlerFocus: Pleural and Peritoneal Mesothelioma

Dr. Kindler's Clinical Research

As Dr. Kindler has a personal interest in the treatment of mesothelioma, much of her research is focused on novel treatments. This research holds potential to not only improve the survival times of patients but also lead to more personalized treatment options.

“The Role of Gemcitabine in the Treatment of Mesothelioma”

Dr. Kindler published this article back in 2002 to discuss the efficacy of the chemotherapy drug, gemcitabine, as a single agent or in combination with a platinum-based chemotherapy drug. What makes the article interesting is that Dr. Kindler suggests other roles the drug may play. The most notable role she suggests in the study is gemcitabine in combination “with other cytotoxic chemotherapy agents such as pemetrexed or vinorelbine, or adding novel cytostatic agents…such as bevacizumab.”

“Moving Beyond Chemotherapy”

Following her article in 2002, Dr. Kindler published an article 2 years later titled, “Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.” The study evaluated the efficacy of novel drugs such as bevacizumab, which work by interfering with the signaling pathways that affect mesothelioma cell growth. Years later, this research has shown to have a significant survival benefit to mesothelioma patients.

Many patients have opened up new treatment options and even reached remission by enrolling in clinical trials. Get access to new mesothelioma treatments by enrolling in clinical trials.

Learn how survivors have beat the odds by enrolling in clinical trials and seeing specialists like Dr. Kindler in our free Mesothelioma Survivors Guide.